NCT02064049View on ClinicalTrials.gov

Surveillance and Treatment of Prisoners With Hepatitis C

PHASE4CompletedINTERVENTIONAL
Enrollment

3,692

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2019

Conditions
Hepatitis C
Interventions
DRUG

Sofosbuvir/velpatasvir

The treatment phase will commence in year 2. This is 12 weeks of the pangenotypic sofosbuvir/velpatasvir 400/100mg, coformulated into one tablet daily.

Trial Locations (4)

2580

Goulburn Correctional Centre, Goulburn

2756

Dillwynia Correctional Centre, Windsor

Outer Metropolitan Multipurpose Correctional Centre, Windsor

2790

Lithgow Correctional Centre, Lithgow

Sponsors

Lead Sponsor

Kirby Institute
All Listed Sponsors
lead

Kirby Institute

OTHER_GOV